Calixa Therapeutics

Calixa Therapeutics was a privately held, San Diego-based biopharmaceutical company focused on developing antibiotics to treat serious infections caused by multi-drug-resistant Gram-negative bacterial pathogens. Its lead compound, CXA-201 (later ceftolozane/tazobactam), was an intravenous therapy for serious hospital-acquired Gram-negative infections. Calixa was acquired by Cubist Pharmaceuticals in December 2009 for approximately $92.5 million (plus up to $310 million in milestone payments) and no longer operates as an independent company. It has no public developer or API surface. This profile exists in the API Evangelist network as a portfolio-lead stub associated with canaan-partners; there are no API artifacts to enrich because it is a defunct pharmaceutical company, not an API provider.

Calixa Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Pharmaceuticals, Biotechnology, Antibiotics, and Anti-Infectives.

🌐 Visit website 📡 Source on GitHub

2.2/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-20 · rubric v0.12.0

0 APIs

Company Pharmaceuticals Biotechnology Antibiotics Anti-Infectives Drug Development Life Sciences Healthcare Acquired

Kin Score

Kin Score How this is scored →
scored 2026-08-20 · rubric v0.12.0

Composite quality — 2.2/100 · minimal

Contract Quality 0.0 / 21

Developer Ergonomics 0.0 / 17

Access Clarity 0.0 / 17

Operational Transparency 0.0 / 11

Contract Governance 0.0 / 10

Discoverability 4.3 / 9

Regulatory Posture 0.0 / 15

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

Documented Reversibility 0 / 6

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.

The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/calixa-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Source (apis.yml)

aid: calixa-therapeutics
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/calixa-therapeutics.png
name: Calixa Therapeutics
description: Calixa Therapeutics was a privately held, San Diego-based biopharmaceutical company focused on developing antibiotics
  to treat serious infections caused by multi-drug-resistant Gram-negative bacterial pathogens. Its lead compound, CXA-201
  (later ceftolozane/tazobactam), was an intravenous therapy for serious hospital-acquired Gram-negative infections. Calixa
  was acquired by Cubist Pharmaceuticals in December 2009 for approximately $92.5 million (plus up to $310 million in milestone
  payments) and no longer operates as an independent company. It has no public developer or API surface. This profile exists
  in the API Evangelist network as a portfolio-lead stub associated with canaan-partners; there are no API artifacts to enrich
  because it is a defunct pharmaceutical company, not an API provider.
url: https://raw.githubusercontent.com/api-evangelist/calixa-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- canaan-partners
x-tier: stub
x-tier-reason: portfolio-lead
x-status: acquired
x-status-note: Acquired by Cubist Pharmaceuticals in December 2009; not an independent operating company and has no public
  API surface.
x-acquired-by: cubist-pharmaceuticals
x-acquired-date: '2009-12-16'
x-industry: pharmaceuticals
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-07-18'
tags:
- Company
- Pharmaceuticals
- Biotechnology
- Antibiotics
- Anti-Infectives
- Drug Development
- Life Sciences
- Healthcare
- Acquired
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence